Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Humanigen, Inc.    HGEN

HUMANIGEN, INC.

(HGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

NIH starts clinical trial testing antibody treatments in COVID-19 patients

10/13/2020 | 11:29am EST

Oct 13 (Reuters) - The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patients as part of the agency's program to identify promising drugs to help tackle the new coronavirus.

The trial will test AbbVie Inc's psoriasis drug risankizumab along with Gilead Sciences' antiviral remdesivir, compared to a placebo and remdesivir.

The study will also test Humanigen's experimental drug lenzilumab with remdesivir, compared to placebo and remdesivir. (https://bit.ly/3lKi1km)

"The goal here is to identify as quickly as possible the experimental therapeutics that demonstrate the most clinical promise as COVID-19 treatments and move them into larger-scale testing," said NIAID Director and U.S. infectious diseases expert Anthony Fauci.

Gilead's remdesivir, which was among the first to be used to treat COVID-19 and received emergency use authorization from the U.S. Food and Drug Administration in May, has since been authorized for use in several other countries.

Risankizumab and lenzilumab belong to a class of drugs known as monoclonal antibodies that are laboratory-made versions of proteins naturally produced by the immune system in response to invading viruses or other pathogens.

The treatment has come under the spotlight after U.S. President Donald Trump was treated with Regeneron Pharmaceuticals' antibody drug earlier this month.

Regeneron and Eli Lilly have both applied to the U.S. FDA for emergency use of their antibody treatments. (Reporting by Amruta Khandekar; editing by Ankur Banerjee and Ramakrishnan M.)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 2.14% 106.98 Delayed Quote.18.30%
GILEAD SCIENCES, INC. 0.97% 61.445 Delayed Quote.-6.34%
HUMANIGEN, INC. 4.73% 9.75 Delayed Quote.281.54%
REGENERON PHARMACEUTICALS -1.17% 492.652 Delayed Quote.32.85%
All news about HUMANIGEN, INC.
11/24HUMANIGEN : Australia Proprietary Limited Established to Facilitate Asia-Pacific..
AQ
11/23HUMANIGEN : Australia Proprietary Limited Established to Facilitate Asia-Pacific..
BU
11/12HUMANIGEN, INC : Results of Operations and Financial Condition, Financial Statem..
AQ
11/11HUMANIGEN : Reports Third Quarter and Nine Months Ended September 30, 2020 Finan..
BU
11/10HUMANIGEN : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
11/09HUMANIGEN : Announces Positive Interim Phase 3 Data of Lenzilumab in Patients Ho..
AQ
11/09HUMANIGEN : Announces Cooperative Research and Development Agreement with the De..
AQ
11/06HUMANIGEN : Announces Positive Interim Phase 3 Data of Lenzilumab™ in Pati..
BU
11/06HUMANIGEN, INC : Entry into a Material Definitive Agreement, Regulation FD Discl..
AQ
11/06HUMANIGEN : Announces Cooperative Research and Development Agreement with the De..
BU
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -99,6 M - -
Net cash 2020 46,0 M - -
P/E ratio 2020 -4,94x
Yield 2020 -
Capitalization 480 M 480 M -
EV / Sales 2020 -
EV / Sales 2021 0,78x
Nbr of Employees 2
Free-Float 59,7%
Chart HUMANIGEN, INC.
Duration : Period :
Humanigen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HUMANIGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 28,50 $
Last Close Price 9,30 $
Spread / Highest target 266%
Spread / Average Target 206%
Spread / Lowest Target 169%
EPS Revisions
Managers
NameTitle
Cameron Durrant Chairman & Chief Executive Officer
Timothy E. Morris Chief Operating & Financial Officer
Dale B. Chappell Chief Scientific Officer
Omar Ahmed Senior VP-Clinical, Medical & Scientific Affairs
Ronald Barliant Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
HUMANIGEN, INC.281.54%480
CSL LIMITED6.54%99 592
SAMSUNG BIOLOGICS CO.,LTD.90.53%48 767
BIOGEN INC.-17.74%37 561
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.180.53%32 774
ALEXION PHARMACEUTICALS, INC.13.50%26 493